Total Payments
$6,626
2024 Payments
$1,804
Companies
44
Transactions
367
Medicare Patients
1,920
Medicare Billing
$416,609
Payment Breakdown by Category
Food & Beverage$6,549 (98.8%)
Education$77.00 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,549 | 366 | 98.8% |
| Education | $77.00 | 1 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,611 | 129 | $0 (2024) |
| MDD US Operations, LLC | $602.21 | 12 | $0 (2024) |
| PFIZER INC. | $425.79 | 30 | $0 (2024) |
| UCB, Inc. | $354.03 | 13 | $0 (2024) |
| EMD Serono, Inc. | $253.55 | 11 | $0 (2024) |
| Lilly USA, LLC | $252.74 | 13 | $0 (2024) |
| CSL Behring | $245.97 | 14 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $239.75 | 10 | $0 (2024) |
| Biogen, Inc. | $229.33 | 10 | $0 (2024) |
| SK Life Science, Inc. | $205.31 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,804 | 79 | ABBVIE INC. ($453.51) |
| 2023 | $2,755 | 168 | ABBVIE INC. ($682.96) |
| 2022 | $1,662 | 104 | ABBVIE INC. ($474.15) |
| 2021 | $405.41 | 16 | AstraZeneca Pharmaceuticals LP ($92.13) |
All Payment Transactions
367 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/20/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: Immunology | ||||||
| 08/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $8.77 | General |
| Category: NEUROSCIENCE | ||||||
| 07/14/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: PAIN | ||||||
| 06/17/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $10.74 | General |
| Category: NEUROSCIENCE | ||||||
| 06/10/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: NEUROSCIENCE | ||||||
| 06/06/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: Musculoskeletal | ||||||
| 06/03/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: NEUROSCIENCE | ||||||
| 05/31/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $25.28 | General |
| Category: PAIN | ||||||
| 05/30/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $19.95 | General |
| 05/30/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: EPILEPSY | ||||||
| 05/30/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: NEUROSCIENCE | ||||||
| 05/23/2024 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $25.67 | General |
| Category: NEUROSCIENCE | ||||||
| 05/22/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 05/20/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $27.26 | General |
| Category: NEUROSCIENCE | ||||||
| 05/16/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $16.59 | General |
| Category: Neurology | ||||||
| 05/16/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $10.72 | General |
| Category: PAIN | ||||||
| 05/14/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $11.63 | General |
| Category: NEUROSCIENCE | ||||||
| 05/13/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/10/2024 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: Neuroscience | ||||||
| 05/07/2024 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: Central Nervous System | ||||||
| 05/06/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $12.13 | General |
| Category: NEUROSCIENCE | ||||||
| 05/04/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: AMANTADINE | ||||||
| 05/01/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: Immunology | ||||||
| 04/29/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Neuropsychiatry | ||||||
| 04/29/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 729 | 1,349 | $682,384 | $160,941 |
| 2022 | 8 | 825 | 1,410 | $734,729 | $177,549 |
| 2021 | 6 | 366 | 609 | $327,727 | $78,118 |
Total Patients
1,920
Total Services
3,368
Medicare Billing
$416,609
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 207 | 426 | $170,400 | $60,535 | 35.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 161 | 496 | $244,032 | $48,610 | 19.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 139 | 143 | $119,691 | $19,726 | 16.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 97 | 97 | $53,350 | $16,552 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 77 | 137 | $47,950 | $13,178 | 27.5% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2023 | 35 | 37 | $35,261 | $1,732 | 4.9% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 13 | 13 | $11,700 | $608.66 | 5.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 147 | 269 | $107,600 | $41,240 | 38.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 158 | 482 | $237,144 | $40,938 | 17.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 125 | 257 | $89,950 | $28,575 | 31.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 154 | 154 | $84,700 | $28,570 | 33.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 148 | 153 | $128,061 | $24,545 | 19.2% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 14 | 14 | $23,996 | $5,937 | 24.7% |
| 99483 | Assessment of and care planning for impaired thought processing, typically 50 minutes | Office | 2022 | 20 | 20 | $7,000 | $4,779 | 68.3% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 33 | 35 | $31,500 | $1,698 | 5.4% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2022 | 26 | 26 | $24,778 | $1,269 | 5.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 71 | 223 | $109,716 | $19,437 | 17.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 62 | 108 | $43,200 | $17,091 | 39.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 87 | 87 | $47,850 | $16,712 | 34.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 84 | 90 | $75,330 | $15,112 | 20.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 37 | 74 | $25,900 | $8,423 | 32.5% |
| 95819 | Measurement and recording of brain wave (eeg) activity, awake and asleep | Facility | 2021 | 25 | 27 | $25,731 | $1,343 | 5.2% |
About Ryan Bowes
Ryan Bowes is a Epilepsy healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/07/2016. The National Provider Identifier (NPI) number assigned to this provider is 1811351687.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ryan Bowes has received a total of $6,626 in payments from pharmaceutical and medical device companies, with $1,804 received in 2024. These payments were reported across 367 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($6,549).
As a Medicare-enrolled provider, Bowes has provided services to 1,920 Medicare beneficiaries, totaling 3,368 services with total Medicare billing of $416,609. Data is available for 3 years (2021–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Epilepsy
- Other Specialties Student in an Organized Health Care Education/Training Program, Neurology
- Location Los Angeles, CA
- Active Since 04/07/2016
- Last Updated 10/15/2024
- Taxonomy Code 2084E0001X
- Entity Type Individual
- NPI Number 1811351687
Products in Payments
- QULIPTA (Drug) $889.99
- UBRELVY (Drug) $473.56
- Apokyn (Drug) $394.97
- NURTEC ODT (Drug) $315.63
- Hizentra (Biological) $245.97
- BOTOX (Biological) $238.41
- INBRIJA (Drug) $189.78
- Fintepla (Drug) $186.00
- RYTARY (Drug) $180.25
- EMGALITY (Drug) $159.22
- VUMERITY (Drug) $158.77
- Aimovig (Biological) $144.35
- APOKYN (Drug) $139.20
- BRIUMVI (Drug) $132.75
- VALTOCO (Drug) $126.91
- AUBAGIO (Drug) $106.52
- VYVGART (Drug) $104.61
- AUSTEDO (Drug) $102.60
- AMYVID (Drug) $93.52
- COMIRNATY (Biological) $90.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.